Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349749 | 0.88 | PARP10 (0.71) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL2516394 | 0.85 | PARP10 (0.68) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL123733 | 0.84 | FFAR1 (0.62) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL31307754 | 0.84 | FFAR1 (0.62) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL5609808 | 0.83 | NPC1 (0.64) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL25034484 | 0.82 | FFAR1 (0.76) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL30874126 | 0.82 | FFAR1 (0.76) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL27968574 | 0.80 | FFAR1 (0.58) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL15249121 | 0.80 | PARP10 (0.61) | FFAR1AKR1B1PARP10MEN1KMT2A | |
| SCHEMBL1746720 | 0.80 | FFAR1 (1.00) | FFAR1AKR1B1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-2857018-A1 | Treatment or prophylaxis of proliferative conditions | University Court of The University of Dundee (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2015-01-08 | — | — | US | disclosed |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| CN-102458394-A | Treatment or prevention of proliferative conditions | UNIV DUNDEE | 2012-05-16 | — | — | CN | disclosed |
| EP-2424524-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | FFAR1 3307/4885AKR1B1 32/4885PARP10 2267/4885 |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | FFAR1 2519/4885AKR1B1 12/4885PARP10 1723/4885 |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | FFAR1 3307/4885AKR1B1 32/4885PARP10 2267/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | FFAR1 2519/4885AKR1B1 12/4885PARP10 1723/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | FFAR1 2519/4885AKR1B1 12/4885PARP10 1723/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | FFAR1 2805/4885AKR1B1 12/4885PARP10 1427/4885 |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | FFAR1 2470/4885AKR1B1 16/4885PARP10 1447/4885 |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | FFAR1 2519/4885AKR1B1 12/4885PARP10 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.